UBS Group’s Achieve Life Sciences ACHV Stock Holding History

UBS Group’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Hold	0	–	-$1K	–	8720
2014 Q4	–	Hold	0	–	–	–	9519

Other funds holding ACHV

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

UBS Group's ACHV Position: Q2 2026 in Review

UBS Group reduced its Achieve Life Sciences (ACHV) stake by 4.1% in Q2 2026, selling an estimated $63.3K and leaving 313,004 shares worth $2.04M. The position accounts for ﹤0.01% of the portfolio, ranked #5098.

UBS Group first reported a position in ACHV in Q4 2014 and has held it in 37 quarters since. 111 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

UBS Group held 313,004 shares of Achieve Life Sciences worth $2.04M as of Q2 2026.
UBS Group sold 13,266 Achieve Life Sciences shares in Q2 2026, an estimated $63.3K.
Achieve Life Sciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5098 holding.
UBS Group first reported a position in Achieve Life Sciences in Q4 2014 and has held it in 37 quarters since.
111 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.